Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Indoor UV tanning causes skin cancer

Indoor UV tanning causes skin cancer

The U.S. Surgeon General should declare that indoor ultraviolet radiation tanning causes skin cancer, according to an article published today by the American Journal of Preventive Medicine. [More]
Study finds no strong link between lung cancer risk and reproductive history variables

Study finds no strong link between lung cancer risk and reproductive history variables

The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for a role of hormone use in the incidence of lung cancer. [More]
Research finding may lead to new potential therapeutic targets for lung cancer

Research finding may lead to new potential therapeutic targets for lung cancer

Lung cancer is the second most common type of cancer and the number one cause of cancer-related mortality. It is estimated that more than 158,000 people will die from lung cancer in the United States this year. Many scientists believe that targeting a type of cell called a cancer stem cell may be necessary to completely cure lung cancer. [More]
Graphic warning labels can motivate smokers to quit

Graphic warning labels can motivate smokers to quit

Young adults are more likely to appreciate the dangers of smoking when warnings are presented in images as well as text, according to a new study by a Washington State University Vancouver psychologist. [More]
Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). [More]
Personalized cancer vaccines can be used to marshal powerful immune response

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. [More]
Simple test outperforms current standard test for early-stage prostate cancer

Simple test outperforms current standard test for early-stage prostate cancer

A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer. [More]
Exercise and physical activity improve lung cancer outcomes

Exercise and physical activity improve lung cancer outcomes

Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer. [More]
Some older people are diagnosed with cancer after emergency admission to hospital

Some older people are diagnosed with cancer after emergency admission to hospital

People over 60 are at higher risk of being diagnosed with lung or bowel cancer as an emergency in hospital than younger people, according to a Cancer Research UK-supported report, published today by BMJ Open. [More]
Combined therapy boosts growth in short children with low IGF-1

Combined therapy boosts growth in short children with low IGF-1

Children with short stature benefit from receiving combined treatment with growth hormone and insulin-like growth factor-1, if they have low endogenous levels of the latter, a study shows. [More]
CVD risk assessment still important in severely obese adolescents

CVD risk assessment still important in severely obese adolescents

Researchers report a dose–response relationship between body mass index and cardiovascular risk even in severely obese adolescents, making its assessment important to limit further disease progression. [More]
Intensive therapy needed in paediatric triiodothyronine-predominant Graves' disease

Intensive therapy needed in paediatric triiodothyronine-predominant Graves' disease

Paediatric patients with triiodothyronine-predominant Graves' disease develop severe disease that needs increased doses of antithyroid drugs, a study shows. [More]
Idiopathic central precocious puberty on the rise in boys

Idiopathic central precocious puberty on the rise in boys

About three-quarters of cases of central precocious puberty in boys have no identifiable cause, say researchers. [More]
Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study. [More]
Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year. [More]
Less-toxic drug combined with fasting may kill cancer cells

Less-toxic drug combined with fasting may kill cancer cells

Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well. [More]
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]
Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. [More]
TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA. [More]
Cancer-specific mortality lower in Asian Americans than non-Hispanic whites, shows study

Cancer-specific mortality lower in Asian Americans than non-Hispanic whites, shows study

Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been diagnosed with cancer, until now. [More]
Advertisement